Relationship between serum b2-microglobulin levels and virological breakthrough in HBeAg-negative chronic hepatitis B patients, under long-term treatment schedules including lamivudine

World Journal of Gastroenterology

Volumn 11, Issue 13, 2005, Pages 1922-1928

  Elefsiniotis, Ioannis S ^a,d   Moulakakis, Antonios ^a   Pantazis, Konstantinos D ^a   Glynou, Irene ^b   Ketikoglou, Ioannis ^a   Vezali, Elena ^a   Kada, Helen ^b   Tsianos, Epameinondas ^c  

^a HIPPOKRATION HOSPITAL   (Greece)

^b HELENA VENIZELOU HOSPITAL   (Greece)

^c UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^d NONE   (Greece)

Author keywords

B2 microglobulin; Chronic hepatitis B; Interferon; Lamivudine; Virological breakthrough

Indexed keywords

ALPHA2A INTERFERON; AMYLASE; BETA 2 MICROGLOBULIN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; AMYLASE BLOOD LEVEL; ARTICLE; CALCULATION; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG ERUPTION; ENZYME IMMUNOASSAY; FATIGUE; FEMALE; FLU LIKE SYNDROME; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LONG TERM CARE; MALE; MONOTHERAPY; MOOD DISORDER; NEUTROPENIA; NONBIOLOGICAL MODEL; NONHUMAN; PREDICTION; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA;

EID: 17144386644     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i13.1922     Document Type: Article

References (35)

1. The World Health Report. WHO 1998
2. Schalm SW, Thomas HB, Hadjiyannis SJ. Chronic hepatitis B. Prog Liver Dis 1990; 9: 443-462
3. Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, Thomas HC. Mutation preventing formation of e antigen in patients with chronic HBV infection. Lancet 1989; 2 588-591
4. Laras A, Koskinas J, Avgidis K, Hadziyannis SJ. Incidence and clinical significance of hepatitis B virus precore gene translation initiation mutations in e antigen-negative patients. J Viral Hepatitis 1998; 5: 241-248
5. Brunetto MR, Giarin M, Saracco G, Oliveri F, Calvo P, Capra G, Randone A, Abate ML, Manzini P, Capalbo M. Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B. Gastroenterology 1993; 105: 845-850
6. Hadziyannis S, Bramou T, Makris A, Moussoulis G, Zignego L, Papaioannou C. Interferon alpha-2b treatment of HBeAg negative/serum HBV-DNA positive chronic active hepatitis type B. J Hepatol 1990; 11: S133-S136
7. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF. A one year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339 61-68
8. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, Hawley S, Barber J, Condreay L, Gray DF. Efficacy of lamivudine in patients with hepatitis B e antigennegative/HBV-DNA positive (precore mutant) chronic hepatitis B. Hepatology 1999; 29: 889-896
9. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu PC, Dent JC, Edmundson S, Condreay LD, Chien RN. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001; 33: 1527-1532
10. Akuta N, Suzuki F, Kobayashi M, Matsuda M, Sato J, Takagi K, Tsubota A, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. Virological and biochemical relapse according to YMDD motif mutant type during long-term lamivudine monotherapy. J Med Virol 2003; 71: 504-510
11. Papatheodoridis GV, Dimou E, Laras A, Papadimitropoulos V, Hadziyannis SJ. Course of virologic breakthroughs under long term lamivudine in HBeAg negative precore mutant HBV liver disease. Hepatology 2002; 36: 219-226
12. Rizzetto M. Efficacy of lamivudine in HBeAg-negative chronic hepatitis B. J Med Virol 2002; 66: 435-451
13. Santantonio T, Niro GA, Sinisi E, Leandro G, Insalata M, Guastadisegni A, Facciorusso D, Gravinese E, Andriulli A, Pastore G. Lamivudine/interferon combination therapy in antiHbe positive chronic hepatitis B patients: a controlled pilot study. J Hepatol 2002; 36: 799-804
14. Malaguarnera M, Restuccia S, Di Fazio I, Zoccolo AM, Trovato BA, Pistone G. Serum b2-microglobulin in chronic hepatitis C. Dig Dis Sci 1997; 42: 762-766
15. Freni MA, Ajello A, Spadaro A, Fava A, Calapristi I, Marafioti T, Alessi N, Resta ML, Ferrau O. Class I HLA antigens hepatic display and b2-microglobulin serum values in chronic hepatitis C: effect of treatment with recombinant alpha interferon. Hepatogastroenterology 1997; 44: 1295-1301
16. Quiroga JA, Martin J, Pardo M, Carreno V. Serum levels of soluble immune factors and pathogenesis of chronic hepatitis C and their relation to therapeutic response to interferon-alpha. Dig Dis Sci 1994; 39: 2485-2496
17. Kumashiro R, Ide T, Sasaki M, Murashima S, Suzuki H, Hino T, Morita Y, Miyajima I, Ogata K, Tanaka E, Yoshida H, Tanikawa K, Sata M. Interferon-gamma brings additive antiviral environment when combined with interferon-alpha in patients with chronic hepatitis C. Hepatol Res 2002; 22: 20-26
18. Garcia-Buey L, Lopez-Botet M, Garcia-Sanchez A, Balboa MA, Aramburu J, Garcia-Monzon C, Acevedo A, Moreno-Otero R. Variability in the expression of a beta2-microglobulin epitopes on hepatocytes in chronic type C hepatitis on treatment with interferon. Hepatology 1993; 17: 372-382
19. Wejstal R, Norkrans G, Weiland O, Schvarcz R, Fuchs D, Wachter H, Fryden A, Glaumann H. Lymphocyte subsets and beta2-microglobulin expression in chronic hepatitis C. Effects on interferon-alpha treatment. Clin Exp Immunol 1992; 87: 340-345
20. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699
21. Tatulli I, Francavilla R, Rizzo GL, Vinciguerra V, Ierardi E, Amoruso A, Panella C, Francavilla A. Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B. J Hepatol 2001; 35: 805-810
22. Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, Dhillon A, Moorat A, Barber J, Gray DF. Lamivudine and alpha-interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000; 46: 562-568
23. Buti M, Sanchez F, Cotrina M, Jardi R, Rodriguez F, Esteban R, Guardia J. Quantitative hepatitis B virus DNA testing for the early prediction of the maintenance of response during lamivudine therapy in patients with chronic hepatitis B. J Infect Dis 2001; 183: 1277-1280
24. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Ann Rev Immunol 1995; 13: 29-60
25. Kagi D, Vignaux F, Ledermann B, Burki K, Depraetere V, Nagata S, Hengartner H, Golstein P. Fas and perforin pathways as major mechanisms of T-cell mediated cytotoxicity. Science 1994; 265 528-530
26. Guidotti LG, Ando K, Hobbs MV, Ishikawa T, Runkel L, Schreiber RD, Chisari FV. Cytotoxic T-lymphocytes inhibit hepatitis B virus gene expression by a non-cytolitic mechanism in transgenic mice. Proc Natl Acad Sci USA 1994; 91: 3764-3768
27. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996; 4: 25-36
28. Mosmann TR, Cherwinski H, Bond MW, Gieldin MA, Coffman RL. Two types of murine helper T cell clone I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136: 2348-2357
29. Bjerrum OW, Bjerrum OJ, Borregaard N. B2-microglobulin in neutrophils: An intragranular protein. J Immunol 1987; 138 3913-3917
30. Boni C, Penna A, Ogg GS, Bertoletti A, Pilli M, Cavallo C, Cavalli A, Urbani S, Boehme R, Panebianco R, Fiaccadori F, Ferrari C. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: New perspectives for immune therapy. Hepatology 2001; 33: 963-971
31. Maini MK, Boni C, Lee CK, Larrubia JR, Reignat S, Ogg GS, King AS, Herberg J, Gilson R, Alisa A, Williams R, Vergani D, Naoumov NV, Ferrari C, Bertoletti A. The role of virus-specific CD8 (+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 2000; 191: 1269-1280
32. Michalak TI, Hodgson PD, Churchill ND. Posttranscriptional inhibition of class I major histocompatibility complex presentation on hepatocytes and lymphoid cells in chronic woodchuck hepatitis virus infection. J Virol 2000; 74: 4483-4494
33. Tomita T, Yokosuka O, Tagawa M, Saisho H, Tamura S, Fukuda I, Omata M. Decrease of wild type and precore mutant duck hepatitis B virus replication during lamivudine treatment in white Pekin duck infected with the viruses. J Hepatol 2000; 32: 850-858
34. Marinos G, Naoumov NV, Williams R. Impact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B virus infection. Hepatology 1996; 24: 991-995
35. Suri D, Schilling R, Lopez AR, Mullerova I, Colucci G, Williams R, Naoumov NV. Non-cytolytic inhibition of hepatitis B virus replication in human hepatocytes. J Hepatol 2001; 35: 790-797